Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/41764
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sobey C.G. | en |
dc.contributor.author | Drummond G.R. | en |
dc.date.accessioned | 2021-05-14T14:19:10Z | en |
dc.date.available | 2021-05-14T14:19:10Z | en |
dc.date.copyright | 2014 | en |
dc.date.created | 20140904 | en |
dc.date.issued | 2014-09-04 | en |
dc.identifier.citation | Trends in Endocrinology and Metabolism. 25 (9) (pp 452-463), 2014. Date of Publication: September 2014. | en |
dc.identifier.issn | 1043-2760 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/41764 | en |
dc.description.abstract | NADPH oxidases (NOXs) are reactive oxygen species (ROS)-generating enzymes implicated in the pathophysiology of vascular diseases such as hypertension and stroke. Endothelial cells express four NOX isoforms including the superoxide-generating enzymes NOX1, NOX2, and NOX5 and the hydrogen peroxide-generating enzyme NOX4. Studies on arteries from patients with coronary artery disease, and in animals with experimentally induced hypertension, diabetes, or atherosclerosis, suggest that NOX1, NOX2, and NOX5 promote endothelial dysfunction, inflammation, and apoptosis in the vessel wall, whereas NOX4 is by contrast vasoprotective in increasing nitric oxide bioavailability and suppressing cell death pathways. Based on these findings and promising preclinical studies with the NOX1/NOX2 antagonist, apocynin, we suggest that the field is poised for clinical evaluation of NOX inhibitors as therapeutics for cardiovascular disease. © 2014 Elsevier Ltd. | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Elsevier Inc. (E-mail: usjcs@elsevier.com) | en |
dc.relation.ispartof | Trends in Endocrinology and Metabolism | en |
dc.title | Endothelial NADPH oxidases: Which NOX to target in vascular disease?. | en |
dc.type | Review | en |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.tem.2014.06.012 | en |
dc.publisher.place | United States | en |
dc.identifier.pubmedid | 25066192 [http://www.ncbi.nlm.nih.gov/pubmed/?term=25066192] | en |
dc.identifier.source | 53253494 | en |
dc.identifier.institution | (Drummond, Sobey) Vascular Biology and Immunopharmacology Group, Department of Pharmacology, Monash University, Clayton, VIC, Australia (Drummond, Sobey) Department of Surgery, Monash Medical Centre, Southern Clinical School, Monash University, Clayton, VIC, Australia | en |
dc.description.address | G.R. Drummond, Vascular Biology and Immunopharmacology Group, Department of Pharmacology, Monash University, Clayton, VIC, Australia. E-mail: grant.drummond@monash.edu | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2015 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Diabetes Endothelial dysfunction Hyperlipidemia Hypertension Inflammation NADPH oxidases Reactive oxygen species Selective NOX1/2 inhibitors Vascular disease | en |
dc.identifier.authoremail | Drummond G.R.; grant.drummond@monash.edu | en |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Review | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.